MaxLinear and Australian med-tech firms see market activity

MaxLinear, Inc. shares saw a 5.2% increase during recent trading, reaching a high of $71.24. The semiconductor company has received varied analyst feedback, including a price target of $125.00 from Benchmark and an upgrade to a “buy” rating from Wall Street Zen. The company maintains a market capitalization of $6.47 billion.

In the Australian medical technology sector, 4DMedical Ltd and Telix Pharmaceuticals Ltd present contrasting investment profiles. 4DMedical, valued at $2.07 billion, focuses on respiratory imaging software used in major US hospitals but has not yet reached profitability.

Telix Pharmaceuticals, with a market cap of $6.03 billion, is a commercial-stage biotech specializing in cancer diagnostics. Unlike 4DMedical, Telix has achieved profitability and is currently conducting over 20 clinical trials globally for various cancer treatments.